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Abstract
Background: Risk sharing schemes represent an innovative and important approach to the problems of
rationing and achieving cost-effectiveness in high cost or controversial health interventions. This study
aimed to assess the feasibility of risk sharing schemes, looking at long term clinical outcomes, to determine
the price at which high cost treatments would be acceptable to the NHS.
Methods: This case study of the first NHS risk sharing scheme, a long term prospective cohort study of
beta interferon and glatiramer acetate in multiple sclerosis (MS) patients in 71 specialist MS centres in UK
NHS hospitals, recruited adults with relapsing forms of MS, meeting Association of British Neurologists
(ABN) criteria for disease modifying therapy. Outcome measures were: success of recruitment and follow
up over the first three years, analysis of baseline and initial follow up data and the prospect of estimating
the long term cost-effectiveness of these treatments.
Results: Centres consented 5560 patients. Of the 4240 patients who had been in the study for a least one
year, annual review data were available for 3730 (88.0%). Of the patients who had been in the study for at
least two years and three years, subsequent annual review data were available for 2055 (78.5%) and 265
(71.8%) patients respectively. Baseline characteristics and a small but statistically significant progression of
disease were similar to those reported in previous pivotal studies.
Conclusion: Successful recruitment, follow up and early data analysis suggest that risk sharing schemes
should be able to deliver their objectives. However, important issues of analysis, and political and
commercial conflicts of interest still need to be addressed.
Published: 6 January 2009
BMC Neurology 2009, 9:1 doi:10.1186/1471-2377-9-1
Received: 15 May 2008
Accepted: 6 January 2009
This article is available from: http://www.biomedcentral.com/1471-2377/9/1
© 2009 Pickin et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
BMC Neurology 2009, 9:1 http://www.biomedcentral.com/1471-2377/9/1Background
Risk sharing schemes represent an innovative and impor-
tant approach to the problems of rationing and achieving
cost-effectiveness in high cost or controversial health
interventions. Where such interventions have been shown
to be effective, and randomised controlled trials (RCTs)
are no longer acceptable, careful use of finite resources
demands that health services should pay in proportion to
benefit. The key feature of risk sharing schemes is to rec-
ognise that, for any intervention, price (and therefore cost
to the provider) may be variable whereas effectiveness is
fixed. Therefore, whatever cost-effectiveness threshold we
choose, we should identify the maximum price a health
service is prepared to pay for any given intervention.
Whilst this holds in theory, there has been little experi-
ence of implementing these schemes in practice, until the
Multiple Sclerosis (MS) Risk Sharing Scheme.
The use of Beta-interferon and Glatiramer acetate for mul-
tiple sclerosis has been highly controversial, with claims
of "postcode prescribing" in the UK. A National Institute
for Clinical Excellence (NICE) appraisal of the use of three
beta-interferon products and glatiramer acetate, pub-
lished in January 2002 [1], concluded that they should
not be funded through the National Health Service
(NHS), as the cost per quality adjusted life year (QALY),
estimated by the use of a cost-effectiveness model devel-
oped in ScHARR [2], was too high. In the face of consid-
erable opposition from patient and professional
organisations and pharmaceutical companies, NICE rec-
ommended that the Department of Health and the four
pharmaceutical companies involved in manufacturing the
drugs should find a way to make them available on the
NHS in a cost-effective manner. This led to the MS Risk
Sharing Scheme [3], in which the drugs were funded on
condition that their effect on disease progression was
monitored in a cohort of patients for ten years. Depending
on the results observed, potential adjustments to the price
of the drugs would be made at intervals to achieve an
agreed cost per QALY of no more than £36,000.
We report our experience of undertaking the monitoring
study for the initial phase of this innovative scheme, the
practical, scientific and political challenges encountered,
and lessons for the use of risk sharing schemes for other
high cost interventions.
Methods
Recruitment
Prescribing Disease Modifying Therapies (DMTs) to
patients under the MS Risk Sharing Scheme was permitted
from May 2002 in specialist MS centres. The DMTs
included in the scheme were three beta-interferon prod-
ucts (Avonex, Betaferon and Rebif in two doses) and glat-
iramer acetate (Copaxone). Choice of drug was made
between clinicians and patients according to usual clinical
practice. Recruitment of the centres to the monitoring
study began in August 2002 in centres across the UK.
Eligible patients were those over the age of 18 years pre-
scribed DMTs according to Association of British Neurol-
ogists (ABN) guidelines [4], for whom an assessment of
disability had been made prior to treatment. These were
recruited to the study by the clinical teams in the centres.
Recruitment formally closed at the end of April 2005
though a small number of participants already in the sys-
tem were consented to the study after that time. Patients
are being followed up annually for ten years, whether or
not they switch or discontinue DMT treatment.
Data Collection
Data were collected at baseline assessment and annual
review, and included patient demographics, DMT pre-
scribed and treatment start date, number of relapses, dis-
ease duration, and type of MS. The principal outcome
measure was the Expanded Disability Status Scale (EDSS)
[5], a widely used scale for assessment of disability in MS,
employing a range of scores from 0 (normal neurological
examination) to 10 (death from MS). Data were recorded
on data collection forms and entered onto a study data-
base held at each centre. Anonymised data were exported
electronically to the University of Sheffield at regular
intervals.
Data Quality
Study fieldworkers checked the completeness and accu-
racy of the data recorded in data collection forms on reg-
ular centre visits, and resolved queries with clinical staff.
Once regular data export was achieved, data validation
reports were produced centrally and sent to the fieldwork-
ers for resolution with the centres. These reports were
based on acceptable value ranges identified with the clin-
ical co-ordinators. Data source verification of study data
against patient notes was undertaken for 446 patients in
63 centres. EDSS assessment was undertaken as far as pos-
sible by the same neurologist each year. A study to meas-
ure inter-rater reliability of EDSS assessments scores was
also undertaken. 138 assessments were undertaken on 69
patients from 36 of the participating centres, with two cli-
nicians reviewing each patient.
Ethics
Approval for the study was obtained from South East
Multi-Centre Research Ethics Committee and research
governance approval was obtained from all participating
centres.Page 2 of 8
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Analyses presented in this paper are on data exported up
to 31st January 2006, from patients starting DMTs since
May 2002.
Descriptive analyses
Simple descriptive analyses of frequency and distribution
of data items at baseline and each annual review were
undertaken.
Changes over time
Between baseline and each annual review we compared:
• the proportion of patients switching and stopping DMTs
• the proportion of patients with secondary progressive
MS
• annual relapse rates.
We also measured disease progresion by the average
change in EDSS score per year between baseline and final
review for each patient, and examined the distribution of
the changes in sub-groups of patients.
Tests were undertaken for heterogeneity in progression in
EDSS scores between subgroups defined on characteristics
identified in the literature and in the natural history
cohort to be prognostic factors i.e. age at baseline (as a
proxy for age at onset), sex, relapse rate and rate of early
progression, prior to DMT [6]. Early progression rate was
estimated as the mean annual change in EDSS score
between reported date of symptom onset and baseline,
assuming an EDSS score of zero at symptom onset.
Results
Recruitment
71 centres agreed to participate in the Risk Sharing
Scheme, and reported prescribing DMTs to 6577 patients
between 1st May 2002 and close of recruitment to the
study on 30th April 2005. 5560 (85%) of these patients
were consented to the monitoring study by 70 of the cen-
tres. Excluding 277 patients withdrawn from the study,
data on 4966 were exported electronically and were avail-
able for analysis. The majority (72%) of withdrawals were
because they were found, after consent, not to have met
the eligibility criteria. Data were excluded for the further
79 patients who started DMT prior to May 2002 and the
16 patients for whom information about start date was
not recorded. The remaining 4,871 patients are included
in this analysis, with follow up ranging from 9 to 44
months.
Data Quality
6050 annual reviews were included in the analysis. Of the
4240 patients who had been in the study for a least one
year, annual review data were available for 3730 (88.0%).
Of the patients who had been in the study for at least two
years and three years, subsequent annual review data were
available for 2055 (78.5%) and 265 (71.8%) patients
respectively. Data were missing either because the assess-
ments had not been done or the data had not been
received at the co-ordinating centre at the time of analysis.
Analyses of the baseline characteristics of patients with
and without annual review were similar, suggesting that
data could be treated as missing at random. 79.4% of first
annual reviews were undertaken by the clinician making
the baseline assessment. The inter-rater reliability exercise
produced Kappa scores of 0.59 (95% CI 0.51, 0.66), 0.71
(95% CI 0.63, 0.79) and 0.85 (95% CI 0.77, 0.93) for full
agreement and agreement to within 0.5 and 1.0 EDSS
score respectively.
For key data items (age, sex, DMT, MS type, EDSS score,
relapses), rates of missing data ranged from 0.01% to
4.9%. Data source verification identified no inconsisten-
cies between data collection forms and patient clinical
records in recorded DMT, four in EDSS score, and 17
(6.9%) in number of relapses.
Baseline characteristics of the participants
Baseline characteristics reflected those reported in other
large pivotal studies of patients on DMTs [7]. Women rep-
resent three quarters of the study cohort (table 1). The
mean age of patients at baseline was 39.3 years, mean
duration of disease from symptom onset was 8.5 years,
and the mean number of years since diagnosis was 5.2
(table 1). The ABN guidelines restrict prescription of
DMTs to patients with two relapsing forms of MS: 85.8%
of patients had relapsing remitting (RR) MS, with the
remainder having a relapsing form of secondary progres-
sive (SP) MS. The distribution of EDSS scores was bimo-
dal with peaks around EDSS 2 and 6 (fig. 1), and a mean
of 3.4, standard deviation (SD) 1.7 (table 1), a pattern
seen in other large cohort studies [6]. The mean EDSS
score for patients with SPMS was 5.5 (SD 1.1) compared
with 3.1 (SD 1.5) for patients with RRMS.
DMT use
DMT use reflects clinical practice as determined by patient
and doctor choice, ABN guidelines and, particularly in
SPMS, licensing regulations. One DMT was prescribed to
almost twice as many patients as the other DMTs (table
1). At first annual review 278 of 3730 (7.5%) patients had
stopped DMT treatment. The cumulative proportion of
stoppers increased to 12.5% (256 of 2055) at second
annual review and to 14.0% (37 of 265) at third annual
review. The proportion of patients switching between
DMTs increased from 3.9% (145 of 3730) at first annual
review to 8.2% (169 of 2055) at second and 13.6% (36 of
265) at third, in line with case series [8].Page 3 of 8
(page number not for citation purposes)
BMC Neurology 2009, 9:1 http://www.biomedcentral.com/1471-2377/9/1Changes over time in MS type, disease progression and 
relapse
For those patients for whom we had data at third annual
review, the proportion with SPMS increased from 14%
(37 of 265) to 25% (67 of 265) from baseline (table 2).
The mean number of relapses in the two years prior to
baseline assessment was 2.9 (table 1). The annual relapse
rate in those patients reaching first annual review reduced
from 1.43 at baseline to 0.66 at first annual review (table
2).
In the 3730 patients who had a first annual review, mean
edss score increased from 3.34 at baseline to 3.45 at AR1
(table 2). This small increase in EDSS score continued
through subsequent ARs with a mean increase of 0.10 to
0.15 per year. The average change per year in EDSS score
for RRMS patients was +0.125 (SE 0.016).
Although there was an increase in mean EDSS at each
annual review, this resulted from a mixture of increases
and decreases (progressions and regressions) for individ-
uals. The distribution of the mean change in EDSS score
for each patient for the time they were in the study is
shown in fig 2. There are almost as many patients with
mean overall regression (n = 913) as progession (n =
1195).
Heterogeneity
The annual EDSS progression rate was one and a half
times higher in men than in women, and in those aged 40
years or over than in younger patients, though only the
latter was statistically significant (table 3). There was no
evidence of any relationship between relapse rate at base-
line and EDSS progression. Mean progression rate
between ARs was slightly higher in those patients with
more rapid progression prior to baseline, though again
this finding was not statistically significant.
Discussion
We have demonstrated that it is feasible to meet the prac-
tical challenges of undertaking a risk sharing scheme
within the NHS. This also illustrates the potential of the
NHS as a 'population laboratory' and further supports the
development of research networks [9]. We have collected
Distribution of EDSS scores at baselineFigure 1
Distribution of EDSS scores at baseline.
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Table 1: Baseline characteristics of patients recruited to start 
DMT for the first time (n = 4871)
Female (%) 3644 (74.9)
RR MS (%) 4176 (85.8)
Age in years, mean (SD) 39.3 (9.1)
Years since diagnosis, mean (SD) 5.2 (5.8)
Years since onset, mean (SD) 8.5 (7.4)
Relapses in prior two years, mean (SD) 2.9 (1.2)
EDSS score, mean (SD) 3.4 (1.7)
DMT (%)
w 1982 (40.7)
x 857 (17.6)
y 1153 (23.7)
z 878 (18.0)Page 4 of 8
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over 5000 patients recruited from 70 centres across the
UK, and continued collection of these data for the remain-
ing seven years of the scheme should allow identification
of a price at which the NHS can provide DMTs in a cost-
effective manner. This is important because the debate
about the cost-effectiveness of DMTs continues, despite
the literature on their effectiveness in certain patients, and
their wide international use [8]. We are not aware of any
other published evidence showing the practicality of
implementing risk sharing schemes.
The MS Risk Sharimg Scheme Monitoring Study has sev-
eral advantages for measuring cost-effectiveness in usual
clinical practice. Because our cohort includes the majority
of patients prescribed DMTs over the recruitment period
in the vast majority of prescribing centres, and since we
have not altered usual clinical practice in these centres, the
external validity of our study is very high. This cohort of
patients represents the vast majority of those prescribed
DMTs according to ABN guidelines over the recruitment
period, and the data collected show the expected demo-
graphic characteristics in terms of age, sex and MS type.
The DMT prescribing pattern in the cohort reflects clinical
practice in the UK, though the considerable variation
found between centres requires further investigation. The
study already has follow up as long as any published RCT
and will be the largest cohort of DMT treated patients with
long term follow up. The ScHARR MS model predicts long
term EDSS progression under DMT treatment using natu-
ral history data from a cohort of Canadian MS patients
followed up for 25 years, together with a reanalysis of RCT
data on the impact of treatments on progression [2,6].
There are no concurrent control patients, and it has been
Table 2: MS type, relapse rate and mean EDSS score at each annual review point
Patients with AR1 (n = 3730) Patients with AR2 (n = 2055) Patients with AR3 (n = 265)
Baseline AR1 Baseline AR2 Baseline AR3
SP MS (%) 536 (14) 664 (18) 323 (16) 456 (22) 37 (14) 67 (25)
Annual relapse rate, mean (SD) 1.43 (0.56) 0.66 (0.91) 1.48 (0.65) 0.58 (0.88) 1.40 (0.56) 0.46 (0.76)
EDSS score, mean (SD) 3.34 (1.67) 3.45 (1.84) 3.51 (1.69) 3.76 (1.94) 3.59 (1.65) 4.00 (1.97)
Distribution of each patient's average annual EDSS score changeFigure 2
Distribution of each patient's average annual EDSS score change.
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appropriate than the MS Risk Sharing Scheme [10]. How-
ever, it would have been unacceptable to many patients
and clinicians to randomise to no treatment (since benefit
on relapse rates has already been proven). Randomising
between DMT products was not acceptable to the pharma-
ceutical companies who were parties to the Risk Sharing
Scheme. The study will also enable accurate estimation of
rates of switching and stopping DMTs as well as the costs
and quality of life associated with different EDSS states
which it is essential to know to accurately estimate the
cost-effectiveness of the DMTs. We have ensured a com-
plete transmission of all entered data at the time of the
analysis reported here, locking the database on 31st Janu-
ary 2006. In these data between 12.0% (for those in the
study at least one year) and 28.2% (for those in the study
at least 3 years) of interim EDSS review scores were miss-
ing. However, the cost-effectiveness analysis linked to
pricing, proposed in the original Health Service Circular
[3], will not use these interim scores. The analysis depends
only on the baseline score and the last confirmed score
collected before analysis. Recording final review scores
will therefore be a priority for future data collection. Cost-
effectiveness may differ between subgroups of patients at
different stages of the disease and subgroup analyses will
be important to address this.
Over the first three years, we have found small but statis-
tically significant progression of disease, as measured by
mean EDSS changes, in MS patients on DMTs. This is con-
sistent with previous, short term, RCTs where the small
changes observed have made it difficult to assess the effect
of DMTs on disease progression [7]. However, the small
changes in mean EDSS between baseline and each annual
review mask considerable variation in individual patients.
At annual reviews EDSS scores have decreased almost as
often as increased, compared to baseline. This variation
could be due to a number of factors. With EDSS, as with
any outcome measure, there is some intra- and inter-
observer variation, though when we restricted our analysis
to patients whose EDSS assessment was made by the same
clinician at baseline and annual review, the findings were
unaffected. It is also possible that the patients whose EDSS
scores have decreased were still recovering from relapse at
the time of baseline assessment. A third possibility is that
the lower EDSS scores represent true (if temporary) regres-
sions in disability in these patients. Without a control
group, it is hard to say whether this level of regression is
due to the effect of DMTs, or whether it occurs in the dis-
ease's natural history, though by the end of the ten year
follow up, there will be a much clearer picture of overall
progression on these drugs. The annual relapse rate at first
annual review was reduced by 54% compared to baseline.
However, differences in the estimation of relapse rate at
baseline and at annual review and the possibility of a
regression to the mean caused by patients with temporar-
ily high relapse rates being entered into the scheme mean
that caution is required in interpreting this finding. Nev-
ertheless, the reduction observed is in line with that seen
in previous RCTs [7]. The results from data source verifi-
cation, the inter-rater reliability study and low rates of
missing data are supportive of data quality, as is the EDSS
distribution pattern, which is as would be expected from
previous cohort studies [6].
Our data indicate possible heterogeneity in disease pro-
gression in specific population subgroups. In particular,
older age at disease onset may be associated with faster
rate of progression in disability. This heterogeneity is con-
sistent with other recently published reports [11,12], and
has implications for the future planned analyses of the
data to determine potential price adjustments. The natural
history cohort used in the analysis should be adjusted
from the Canadian study population to match the charac-
teristics of patients entering the Risk Sharing Scheme. It is
also important that the natural history data is validated,
since there is evidence that the incidence of MS is chang-
ing and that the natural history may be becoming more
Table 3: Mean annual EDSS score change by potential prognostic factors
Mean N Std. Error of Mean Test P
Sex Male 0.169 783 0.031 Mann-Whitney 0.204
Female 0.111 2399 0.018
Age at baseline 0–39 0.102 1803 0.021 Mann-Whitney 0.014
40+ 0.155 1381 0.023
Relapses in two years prior to baseline 2 0.146 1480 0.023 Kruskal-Wallis 0.878
3 0.099 954 0.029
4+ 0.116 750 0.032
Progression rate prior to baseline (>2 reviews) 0 to 0.464 0.169 775 0.033 Mann-Whitney 0.455
>0.464 0.213 806 0.035Page 6 of 8
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assessment of cost-effectiveness of the different DMTs,
case-mix adjustment will be necessary. Further complexity
is added by patients switching and stopping drugs, and
this needs to be addressed in the analysis. Additionally,
the cost effectiveness may depend on characteristics that
influence responsiveness such as neutralising antibodies
and relapse frequency.
We have shown that the practical difficulties in establish-
ing the Risk Sharing Scheme can be overcome, and the sci-
entific challenges we have identified can be addressed
through appropriate methods of analysis. However, per-
haps the most important threat to the NHS's ability to
determine the cost-effectiveness of DMTs comes from the
tensions inherent in such a scheme. These arise from the
differing interests of the Department of Health, the phar-
maceutical companies, researchers and patients. The com-
mercial risks associated with the scheme led to the
involvement of the companies as well as the Department
of Health in the scheme's governance. The scheme was
retendered but the ScHARR consortium decided not to
apply as they were not happy with the proposed arrange-
ments for data access and publication rights, and the
scheme is now being undertaken by a contract research
organisation. The data that is being collected by the con-
tract research organisation for use in future publications
may not be the same as the data we have presented here.
The data from the scheme is owned by the MS Trust.
Conclusion
Whilst it has been possible to meet the operational chal-
lenges in delivering the MS Risk Sharing Scheme, impor-
tant scientific challenges and conflicts of interest remain
in this highly controversial area. Risk sharing schemes rep-
resent an important way for health services to ensure cost-
effective provision of high cost health care interventions,
so long as the research is independent of the parties to the
schemes.
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